Rapid Communication
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Aug 28, 2008; 14(32): 5020-5024
Published online Aug 28, 2008. doi: 10.3748/wjg.14.5020
Figure 1
Figure 1 Individual and overall symptom scores at baseline, based on the visual analogue scale (VAS).
Figure 2
Figure 2 The time of the first rise at or above 10 ppm in breath hydrogen after lactulose during the baseline period, and during treatment with L. casei strain Shirota. The time during the treatment period was significantly later compared to at baseline (P = 0.03, Wilcoxon matched pairs test).
Figure 3
Figure 3 The overall abdominal symptom score at baseline in patients with more than minimal symptoms (VAS < 3 cm), compared with scores at week 6 of treatment, with and without ERBHAL at the conclusion of the treatment. A: Without ERBHAL; B: With continuing ERBHAL. Shading indicates the minimal symptom score category. These changes were statistically not significant.